Alnylam Pharmaceuticals
Stock Forecast, Prediction & Price Target

Alnylam Pharmaceuticals (ALNY) stock Price Target by analysts

Last Year
Average Price Target

$336.33

Potential downside: -25.11%

Based on 2 analysts

Alnylam Pharmaceuticals price prediction

Strike.market

What is Alnylam Pharmaceuticals stock analysts` prediction?

Alnylam Pharmaceuticals stock forecast: Based on 2 Wall Street analysts` predicted price targets for Alnylam Pharmaceuticals in the last 3 months, the avarage price target is $336.33, with a high forecast of $NaN. The average price target represents a -25.11% change from the last price of $449.12.

Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.

Alnylam Pharmaceuticals stock Price Target by analysts

Full breakdown of analysts given Alnylam Pharmaceuticals price targets

Analyst name & company
Analyst win rate
Publish date
Price target
Price when posted
Source Historical targets
Whitney Ijem
Canaccord Genuity
0%
0/3
10 months ago $336 -25.18% downside $294.87 StreetInsider
Previous targets (2)
Whitney Ijem
Canaccord Genuity
0%
0/3
11 months ago $366 -18.50% downside $273.69 StreetInsider
Previous targets (2)
Tazeen Ahmad
Bank of America Securities
50%
1/2
11 months ago $307 -31.64% downside $274.91 StreetInsider
Previous targets (1)
Kostas Biliouris
BMO Capital
0%
0/2
about 1 year ago $300 -33.20% downside $269.31 StreetInsider
Previous targets (1)
Luca Issi
RBC Capital
20%
1/5
about 1 year ago $300 -33.20% downside $271.43 StreetInsider
Previous targets (4)
Salveen Richter
Goldman Sachs
0%
0/2
about 1 year ago $370 -17.61% downside $262.7 TheFly
Previous targets (1)
Whitney Ijem
Canaccord Genuity
0%
0/3
about 1 year ago $357 -20.51% downside $253.86 StreetInsider
Previous targets (2)
Esther Rajavelu
UBS
50%
1/2
about 1 year ago $288 -35.87% downside $247 StreetInsider
Previous targets (1)
Luca Issi
RBC Capital
20%
1/5
about 1 year ago $265 -40.99% downside $245.17 TheFly
Previous targets (4)
Paul Matteis
Stifel Nicolaus
0%
0/2
about 1 year ago $295 -34.31% downside $247.4 StreetInsider
Previous targets (1)
Luca Issi
RBC Capital
20%
1/5
about 1 year ago $250 -44.33% downside $222.9 TheFly
Previous targets (4)
Liisa Bayko
Evercore ISI
0%
0/1
about 1 year ago $260 -42.10% downside $222.9 TheFly
Previous targets (0)
Andrew Galler
Morgan Stanley
0%
0/1
about 1 year ago $250 -44.33% downside $224.7 StreetInsider
Previous targets (0)
Paul Matteis
Stifel Nicolaus
0%
0/2
about 1 year ago $247 -45.00% downside $227.92 StreetInsider
Previous targets (1)
Patrick Trucchio
H.C. Wainwright
0%
0/1
about 1 year ago $400 -10.93% downside $227.05 TheFly
Previous targets (0)
Luca Issi
RBC Capital
20%
1/5
about 1 year ago $235 -47.67% downside $156.43 StreetInsider
Previous targets (4)
Kostas Biliouris
BMO Capital
0%
0/2
over 1 year ago $234 -47.89% downside $156.59 StreetInsider
Previous targets (1)
Edward Tenthoff
Piper Sandler
50%
1/2
over 2 years ago $253 -43.66% downside $229.37 TheFly
Previous targets (1)
Olivia Brayer
Cantor Fitzgerald
100%
1/1
about 3 years ago $175 -61.03% downside $145.85 TheFly
Previous targets (0)
Edward Tenthoff
Piper Sandler
50%
1/2
about 3 years ago $208 -53.68% downside $135.83 TheFly
Previous targets (1)
Gary Nachman
BMO Capital
100%
1/1
over 3 years ago $175 -61.03% downside $150.76 TipRanks Contributor
Previous targets (0)
Zhiqiang Shu
Berenberg Bank
100%
1/1
over 3 years ago $154 -65.71% downside $150.76 TipRanks Contributor
Previous targets (0)
Luca Issi
RBC Capital
20%
1/5
over 3 years ago $225 -49.90% downside $150.86 TipRanks Contributor
Previous targets (4)
Debjit Chattopadhyay
Guggenheim
100%
1/1
over 3 years ago $170 -62.14% downside $142.51 TheFly
Previous targets (0)
Tazeen Ahmad
Bank of America Securities
50%
1/2
over 3 years ago $209 -53.46% downside $130.12 StreetInsider
Previous targets (1)
Maury Raycroft
Jefferies
100%
1/1
over 3 years ago $205 -54.35% downside $136.53 TipRanks Contributor
Previous targets (0)
Ritu Baral
Cowen & Co.
0%
0/1
over 3 years ago $250 -44.33% downside $186.42 TheFly
Previous targets (0)
Salveen Richter
Goldman Sachs
0%
0/2
almost 4 years ago $273 -39.21% downside $187.01 TheFly
Previous targets (1)
Maneka Mirchandaney
Evercore ISI
100%
1/1
almost 4 years ago $190 -57.69% downside $159.56 TipRanks
Previous targets (0)
Esther Rajavelu
UBS
50%
1/2
almost 4 years ago $211 -53.01% downside $159.56 StreetInsider
Previous targets (1)
Alethia Young
Cantor Fitzgerald
0%
0/1
almost 4 years ago $275 -38.76% downside $159.56 TheFly
Previous targets (0)
Gena Wang
Barclays
100%
1/1
almost 4 years ago $210 -53.24% downside $162.14 Investing
Previous targets (0)

Alnylam Pharmaceuticals Financial Estimates

Alnylam Pharmaceuticals Revenue Estimates

Alnylam Pharmaceuticals EBITDA Estimates

Alnylam Pharmaceuticals Earnings per Share Estimates

Passed Analyst forecast
Metric 12/31/2021 12/31/2022 12/31/2023 12/31/2025 12/31/2026 12/31/2027 12/31/2028
Revenue
 
% change YoY
$844.28M
 
N/A
$1.03B
 
22.87%
$1.82B
 
76.23%
Avg: $2.30B
Low: $1.99B
High: $2.59B
avg. 25.84%
Avg: $3.09B
Low: $2.59B
High: $3.51B
avg. 34.45%
Avg: $4.00B
Low: $3.36B
High: $4.55B
avg. 29.61%
Avg: $5.06B
Low: $4.25B
High: $5.75B
avg. 26.20%
Net Income
 
% change YoY
$-852.82M
 
N/A
$-1.13B
 
-32.63%
$-440.24M
 
61.08%
Avg: $-226.35M
Low: $-472.14M
High: $288.53M
avg. 48.58%
Avg: $307.52M
Low: $-101.17M
High: $1.14B
avg. 235.86%
Avg: $700.81M
Low: $555.19M
High: $824.99M
avg. 127.89%
Avg: $1.29B
Low: $1.02B
High: $1.52B
avg. 84.33%
EBITDA
 
% change YoY
$-709.12M
 
N/A
$-894.43M
 
-26.13%
$-258.24M
 
71.12%
Avg: $-1.76B
Low: $-1.98B
High: $-1.52B
avg. -581.88%
Avg: $-2.36B
Low: $-2.69B
High: $-1.98B
avg. -34.45%
Avg: $-3.06B
Low: $-3.48B
High: $-2.57B
avg. -29.61%
Avg: $-3.87B
Low: $-4.40B
High: $-3.25B
avg. -26.20%
EPS
 
% change YoY
-$7.2
 
N/A
-$9.3
 
-29.16%
-$3.52
 
62.15%
Avg: -$1.64
Low: -$3.78
High: $2.31
avg. 53.33%
Avg: $2.35
Low: -$0.81
High: $9.2
avg. 243.15%
Avg: $5.61
Low: $4.44
High: $6.6
avg. 138.59%
Avg: $10.34
Low: $8.19
High: $12.18
avg. 84.33%
Operating Expenses
 
% change YoY
$1.41B
 
N/A
$1.65B
 
17.04%
$1.80B
 
8.85%
Avg: $2.43B
Low: $2.10B
High: $2.74B
avg. 35.14%
Avg: $3.27B
Low: $2.74B
High: $3.71B
avg. 34.45%
Avg: $4.23B
Low: $3.56B
High: $4.81B
avg. 29.61%
Avg: $5.35B
Low: $4.49B
High: $6.07B
avg. 26.20%

FAQ

What is Alnylam Pharmaceuticals stock earnings growth forecast?

Wall Street analysts estimate the annual average earnings growth rate of 124.16% in 2025-2028.

We have gathered data from 19 analysts. Their low estimate is -472.14M, average is -226.35M and high is 288.53M.

What is Alnylam Pharmaceuticals stock revenue growth forecast?

Wall Street analysts forecast annual average revenue growth of 29.02% in 2025-2028.

We have gathered data from 23 analysts. Their low revenue estimate is $1.99B, average is $2.30B and high is $2.59B.

What is Alnylam Pharmaceuticals stock earnings per share growth forecast?

Wall Street analysts forecast annual average earnings growth of 129.85% in 2025-2028.

We have gathered data from 19 analysts. Their low earnings per share estimate is -$3.78, average is -$1.64 and high is $2.31.

What is the best performing analyst?

In the last twelve months 2 analysts have been covering Alnylam Pharmaceuticals stock. The most successful analyst is Whitney Ijem.